Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Comparison of Holmium Laser Enucleation of the Prostate and Robotic Water Jet Ablation for Benign Prostatic Hyperplasia

14. august 2026 opdateret af: The Methodist Hospital Research Institute

Prospective Randomized Controlled Comparison of Holmium Laser Enucleation of the Prostate With Robotic Water Jet Ablation

This study compares two FDA-approved surgical treatments for benign prostatic hyperplasia (BPH): Holmium Laser Enucleation of the Prostate (HoLEP) with MOSES 2.0 technology and Robotic Water Jet Ablation (RWJA) using the Hydros Robotic System. Men with BPH and prostate volumes between 50 and 180 mL will be randomly assigned to one of the two procedures. The study will measure changes in prostate volume, PSA, urinary flow, and bladder emptying at 12 months, along with safety, sexual function, continence, and healthcare utilization outcomes, which will be followed for up to 5 years after surgery.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

This prospective, randomized controlled trial is designed to compare the safety, effectiveness, and long-term durability of Holmium Laser Enucleation of the Prostate (HoLEP) utilizing MOSES 2.0 technology with Robotic Water Jet Ablation (RWJA) performed using the Hydros Robotic System for the treatment of benign prostatic hyperplasia (BPH). The trial will enroll 100 men aged 50 to 80 years who present with moderate-to-severe lower urinary tract symptoms secondary to BPH and prostate volumes between 50 and 180 mL. Participants will be randomized in a 1:1 ratio to receive either HoLEP or RWJA and will be monitored for five years following treatment.

The primary objective is to compare objective measures of treatment efficacy and durability at 12 months, specifically changes in prostate volume, prostate-specific antigen (PSA) levels, urinary flow rate (Qmax), and post-void residual urine volume (PVR). Secondary objectives include assessment of perioperative outcomes, safety profiles, patient-reported urinary and sexual function, treatment durability, reintervention rates, and healthcare resource utilization. Outcomes will be measured using validated instruments, such as the International Prostate Symptom Score (IPSS), Sexual Health Inventory for Men (SHIM), Male Sexual Health Questionnaire-Ejaculatory Dysfunction (MSHQ-EjD), and Incontinence Severity Index (ISI).

Although both procedures are established and FDA-approved therapies for BPH, direct comparative evidence is limited. This study seeks to address this evidence gap by generating high-quality comparative effectiveness data to inform clinical decision-making and patient counseling. The results may clarify the relative benefits and tradeoffs of each procedure, particularly in terms of symptom improvement, preservation of sexual function, durability of treatment response, and long-term healthcare utilization.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

100

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Beskrivelse

Inclusion Criteria:

  1. Male, age 50-80 years
  2. International Prostate Symptom Score (IPSS) ≥ 12
  3. Prostate size (TRUS): 50-180 mL
  4. Diagnosis of LUTS due to BPH
  5. Uroflow Qmax ≤ 15 mL/sec
  6. Mentally capable, able to comply with study procedures, written informed consent provided
  7. Able to follow study instructions and complete all required visits

Exclusion Criteria:

  1. BMI ≥ 42
  2. History of prostate cancer
  3. Suspected or history of bladder cancer
  4. Active or untreated bladder stones at screening
  5. Indwelling catheter for more than 3 months before baseline
  6. Active urinary tract infection
  7. History of urethral stricture or bladder neck stenosis
  8. Damage to the external urethral sphincter
  9. Previous prostate surgery or lower urinary tract surgery
  10. Use of obligatory anticoagulants (if not stoppable) or known coagulopathy (except ASA 100 mg/d)
  11. Contraindications to general and spinal anesthesia
  12. Any condition that could interfere with study participation or outcomes, per investigator judgment
  13. Lacks legal or mental capacity to consent
  14. Simultaneous participation in another therapeutic urological trial
  15. Known or persistent abuse of medication, drugs, or alcohol

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Andet
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Enkelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: HoLEP with MOSES 2.0
Holmium laser enucleation of the prostate using MOSES 2.0 pulse-modulation technology, performed per institutional standard of care.
Holmium laser enucleation of the prostate using MOSES 2.0 pulse-modulation technology, performed per institutional standard of care.
Aktiv komparator: RWJA with Hydros Robotic System
Robotic-assisted waterjet ablation of the prostate using the Hydros Robotic System, performed per institutional standard of care.
Device - RWJA (Hydros Robotic System) / Aquablation therapy (often referred to by its commercial name, "Aquablation").

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in Prostate Volume
Tidsramme: Baseline and 12 months post-intervention
Measured via transrectal ultrasound (TRUS); change from baseline.
Baseline and 12 months post-intervention
Change in Prostate-Specific Antigen (PSA)
Tidsramme: Baseline and 12 months post-intervention
Serum PSA level; change from baseline.
Baseline and 12 months post-intervention
Change in Urinary Flow Rate (Qmax)
Tidsramme: Baseline and 12 months post-intervention
Peak urinary flow rate via uroflowmetry; change from baseline.
Baseline and 12 months post-intervention
Change in Post-Void Residual Volume (PVR)
Tidsramme: Baseline and 12 months post-intervention
Bladder scan-measured PVR; change from baseline.
Baseline and 12 months post-intervention

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Incidence and Severity of Adverse Events
Tidsramme: From patient hospital discharge through 3 and 12 months post-surgery
Adverse events graded by the Clavien-Dindo classification system.
From patient hospital discharge through 3 and 12 months post-surgery
Operative Time
Tidsramme: Day (duration) of surgical procedure
Total procedure time, start to finish.
Day (duration) of surgical procedure
Hemostasis Time
Tidsramme: Day (duration) of surgical procedure
Time required to achieve hemostasis intraoperatively.
Day (duration) of surgical procedure
Perioperative Change in Hemoglobin
Tidsramme: Baseline to immediate postoperative period (when patient is in the recovery room post surgery)
Hemoglobin level change from baseline to immediate postoperative measurement.
Baseline to immediate postoperative period (when patient is in the recovery room post surgery)
Time to Catheter-Free Status
Tidsramme: From surgery day until catheter removal
Duration from end of surgery to catheter removal.
From surgery day until catheter removal
Length of Hospital Stay / Discharge Time
Tidsramme: Day of surgical procedure through hospital discharge
Time from surgery to hospital discharge.
Day of surgical procedure through hospital discharge
Change in IPSS/QoL Score
Tidsramme: Baseline, 3, 6, and 12 months post-surgery
International Prostate Symptom Score / Quality of Life index.
Baseline, 3, 6, and 12 months post-surgery
Change in SHIM Score
Tidsramme: Baseline, 3, 6, and 12 months post-surgery
Sexual Health Inventory for Men.
Baseline, 3, 6, and 12 months post-surgery
Change in MSHQ-EjD Score
Tidsramme: Baseline, 3, 6, and 12 months post-surgery
Male Sexual Health Questionnaire - Ejaculatory Dysfunction.
Baseline, 3, 6, and 12 months post-surgery
Change in Incontinence Outcomes
Tidsramme: Baseline, 3, 6, and 12 months post-surgery
Incontinence Severity Index (ISI) score and Cough Stress Test (CST) result.
Baseline, 3, 6, and 12 months post-surgery
Long-Term Durability of Functional Improvements
Tidsramme: 24, 36, 48, and 60 months post-intervention
Composite tracking of IPSS, Qmax, PVR, PSA, and prostate volume.
24, 36, 48, and 60 months post-intervention
Post-Operative Medication Use
Tidsramme: Through 60 months post-intervention
Number of prescriptions written and filled (initial fills and refills), e.g., alpha-blockers, 5-alpha reductase inhibitors.
Through 60 months post-intervention
Reintervention Rate
Tidsramme: Through 60 months post-intervention
Repeat procedures or additional therapies for BPH/LUTS.
Through 60 months post-intervention
Unplanned Healthcare Encounters
Tidsramme: Through 60 months post-intervention
Emergency visits, urgent care visits, and add-on clinic visits related to the procedure.
Through 60 months post-intervention
Incidence of Urethral Stricture Requiring Intervention
Tidsramme: Through 60 months post-intervention
New urethral stricture or bladder neck stenosis requiring treatment.
Through 60 months post-intervention
Unanticipated Advanced Diagnostics
Tidsramme: Through 60 months post-intervention
Unplanned MRI, cystoscopy, or prostate cancer biomarker testing.
Through 60 months post-intervention

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

3. august 2026

Primær færdiggørelse (Anslået)

3. august 2029

Studieafslutning (Anslået)

3. august 2033

Datoer for studieregistrering

Først indsendt

9. juli 2026

Først indsendt, der opfyldte QC-kriterier

14. august 2026

Først opslået (Faktiske)

19. august 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

19. august 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

14. august 2026

Sidst verificeret

1. august 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • Pro00041304

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ja

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .